World Rare Disease Day 2026: Raising Awareness and Improving Lives

Saturday, February 28, 2026, marks the 19th annual World Rare Disease Day, a global event dedicated to raising awareness about the challenges faced by individuals living with rare diseases. Although each rare disease affects a small number of people, collectively they impact millions worldwide.

Understanding Rare Diseases

A rare disease is generally defined as one that affects no more than one person in 2,000. In France, between 6,000 and 8,000 rare diseases have been identified, impacting an estimated 3 to 4 million people – representing approximately 4.5% of the population. Across Europe, around 30 million individuals are affected by rare diseases. Source

Despite their individual rarity, the cumulative impact of rare diseases is significant, making them a major public health concern. A concerning statistic reveals that only about half of those affected receive a diagnosis. In France, rare diseases contribute to 10% of deaths between the ages of one and five.

Spotlight on Albinism

This year, the French Society of Dermatology is focusing attention on albinism, a rare genetic condition characterized by a lack of melanin production. Melanin is the pigment responsible for coloring skin, hair, and eyes.

Albinism affects approximately one in 17,000 births globally. Prevalence varies geographically, with rates of one in 2,000 in certain African countries and one in 200 in specific Panamanian islands. It is estimated that nearly 5,000 people in France live with albinism. Source

What is Albinism?

Albinism is a complex genetic disease extending beyond skin and hair color. Professor Smail Hadj-Rabia, a dermatologist at the reference center for genetic skin diseases at Necker Hospital in Paris, emphasizes that “Better knowledge of its mechanisms and national coordination of care now make it possible to significantly improve the care and quality of life of patients.” Source

Common characteristics of albinism include:

• Depigmentation of the skin and hair (ranging from generalized hypopigmentation to partial pigmentation).
• Visual impairment, including low visual acuity, photophobia, and nystagmus (involuntary eye movements).
• Increased sensitivity to ultraviolet (UV) radiation, necessitating diligent sun protection.
• An elevated risk of skin cancers, particularly squamous cell carcinomas.

Types of Albinism

There are approximately twenty different forms of albinism, categorized clinically into three main types:

• Oculocutaneous albinism: Affects both the skin and eyes.
• Ocular albinism: Primarily affects the eyes.
• Syndromic albinism: A rarer form associated with other health issues, such as hematological, immune, pulmonary, or digestive disorders.

Diagnosis and Care

Diagnosing albinism can be challenging, especially in children with fair complexions. Diagnosis relies on clinical examination and is confirmed through genetic testing – a molecular analysis of the 19 known genes involved. However, approximately 15% of individuals with albinism lack a definitive molecular diagnosis, suggesting the involvement of undiscovered genetic factors. Source

Currently, there is no specific drug treatment for albinism, but research is ongoing to understand the mechanisms of pigmentation and ocular development.

Care for individuals with albinism is multidisciplinary and focuses on managing symptoms and preventing complications.

France’s Commitment to Rare Diseases

France has demonstrated a long-standing commitment to rare disease research and care, adopting national plans since 2004. The country is currently implementing its fourth National Rare Diseases Plan (PNMR4), launched in February 2025, with a focus on improved care, accelerated research, and support for innovation. Source

PNMR4 includes an expansion of reference centers for rare diseases, increasing the total to 603 centers nationwide – a 28% increase – with an additional €36 million in funding. Source

France also boasts a robust network of rare disease expertise, including 23 national Rare Disease networks (‘filières de santé maladies rares’ – FSMR), 387 Centres of Reference, and 1844 Centres of Competence. Source